The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

Shilpa  Gupta

Stock and Other Ownership Interests  - BioNTech SE; Moderna Therapeutics; Nektar; Nektar

Honoraria - Bristol Myers Squibb Foundation

Consulting or Advisory Role - EMD Serono; Foundation Medicine; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Natera; Pfizer; Seagen

Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen

Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)

Jonathan E.  Rosenberg

Honoraria - Clinical Care Options; EMD Serono; Medscape; MJH Life Sciences; Peerview; Pfizer; Physicans' Education Resource; Research To Practice; UpToDate

Consulting or Advisory Role - Alligator Bioscience; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Immunomedics; Imvax; Infinity Pharmaceuticals; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)

Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)

Rana R.  McKay

Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Telix Pharmaceuticals; Tempus; Vividion Therapeutics

Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)

Thomas W.  Flaig

Leadership - Aurora Oncology; University of Colorado/UC Health

Stock and Other Ownership Interests  - Aurora Oncology

Consulting or Advisory Role - Janssen Oncology; Seagen

Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seagen; Sotio; Tokai Pharmaceuticals

Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.

Daniel P.  Petrylak

Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma

Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)

Expert Testimony - Celgene; sanofi

Christopher J.  Hoimes

Honoraria - Seagen

Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen

Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen

Research Funding - Alkermes (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); crispr therapeutics (Inst); Dynavax Technologies (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); NanoCarrier (Inst); Nektar (Inst); NeoImmuneTech (Inst); Novartis (Inst); Seagen (Inst)

(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)

Terence W.  Friedlander

Leadership - Med BioGene

Honoraria - Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca/MedImmune; EMD Serono

Consulting or Advisory Role - AADi; Astellas Pharma; Basilea; Dava Oncology; EMD Serono; Foundation Medicine; Merck; Seagen; Taiho Oncology

Research Funding - Bristol-Myers Squibb (Inst); Neon Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca/MedImmune; Genentech/Roche; Jounce Therapeutics

Mehmet Asim  Bilen

Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen

Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)

Sandy  Srinivas

Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen Oncology; Merck; Novartis; Seagen

Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); Seattle Genetics/Astellas (Inst)

Other Relationship - Pfizer

Earle F  Burgess

Stock and Other Ownership Interests  - Arvinas; Becton Dickinson; Calithera Biosciences; Exelixis; Gilead Sciences; Macrogenics; Medtronic

Honoraria - Exelixis; Janssen Oncology; Merck; Novartis; Pfizer

Consulting or Advisory Role - Johnson & Johnson

Speakers' Bureau - AstraZeneca; Exelixis

Research Funding - Astellas Pharma; Pfizer

Jaime R.  Merchan

Consulting or Advisory Role - Merck

Research Funding - BioNTech (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); IMUGENE (Inst); Merck (Inst); Peloton Therapeutics (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Seattle Genetics/Astellas (Inst); Sillajen (Inst); Tizona Therapeutics, Inc. (Inst); Tocagen (Inst); Trishula Therapeutics (Inst); Vyriad (Inst)

Patents, Royalties, Other Intellectual Property - UpToDate

Scott T.  Tagawa

Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar

Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)

Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead

Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi

(OPTIONAL) Uncompensated Relationships - Ambrx; ATLAB Pharma; Phosplatin Therapeutics

Jason R  Brown

Honoraria - AstraZeneca

Speakers' Bureau - EMD Serono

Research Funding - Bicycle Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novita Pharmaceuticals (Inst); Seagen (Inst)

Yao  Yu

Employment - Seagen

Stock and Other Ownership Interests  - Seagen

Anne-Sophie  Carret

Employment - Seagen

Stock and Other Ownership Interests  - Seagen

Honoraria - Seagen

Travel, Accommodations, Expenses - Seagen

Heidi  Wirtz

Employment - Seagen

Stock and Other Ownership Interests  - Amgen; Seagen; Teva

Maria  Guseva

Employment - Astellas Pharma

Blanca  Homet Moreno

Employment - Merck Sharp & Dohme

Stock and Other Ownership Interests  - Merck Sharp & Dohme

Matthew I.  Milowsky

Stock and Other Ownership Interests  - Gilead Sciences; Merck; Pfizer

Consulting or Advisory Role - Loxo/Lilly

Research Funding - Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); G1 Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)

Other Relationship - Elsevier; Medscape